Unique antibody responses to malondialdehyde-acetaldehyde (MAA)-protein adducts predict coronary artery disease

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Anderson, Daniel R ^a   Duryee, Michael J ^a,b   Shurmur, Scott W ^a   Um, John Y ^a   Bussey, Walter D ^a   Hunter, Carlos D ^a,b   Garvin, Robert P ^a   Sayles, Harlan R ^a   Mikuls, Ted R ^a,b   Klassen, Lynell W ^a,b   Thiele, Geoffrey M ^a,b  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b VA NEBRASKA WESTERN IOWA HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETALDEHYDE; HUMAN SERUM ALBUMIN; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; MALONALDEHYDE; MALONDIALDEHYDE ACETALDEHYDE PROTEIN ADDUCT; UNCLASSIFIED DRUG; AUTOANTIBODY; BIOLOGICAL MARKER; LOW DENSITY LIPOPROTEIN;

ACUTE HEART INFARCTION; ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY RESPONSE; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; FEMALE; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; SERUM; STABLE ANGINA PECTORIS; AGED; ATHEROSCLEROTIC PLAQUE; BLOOD; CASE CONTROL STUDY; IMMUNOLOGY; MIDDLE AGED;

ACETALDEHYDE; AGED; AUTOANTIBODIES; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CORONARY ARTERY DISEASE; FEMALE; HUMANS; LIPOPROTEINS, LDL; MALE; MALONDIALDEHYDE; MIDDLE AGED; PLAQUE, ATHEROSCLEROTIC;

EID: 84923544825     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0107440     Document Type: Article

References (51)

1. Libby P, Ridker PM, Hansson GK (2009) Inflammation in atherosclerosis: from pathophysiology to practice. Journal of the American College of Cardiology 54: 2129-2138.
2. Ross R (1999) Atherosclerosis-an inflammatory disease. The New England journal of medicine 340: 115-126.
3. Anderson DR, Poterucha JT, Mikuls TR, Duryee MJ, Garvin RP, et al. (2013) IL-6 and its receptors in coronary artery disease and acute myocardial infarction. Cytokine 62: 395-400.
4. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, et al. (2008) Rosuvastatin to prevent vascular events in men and women with elevated Creactive protein. The New England journal of medicine 359: 2195-2207.
5. Duryee MJ, Klassen LW, Schaffert CS, Tuma DJ, Hunter CD, et al. (2010) Malondialdehyde-acetaldehyde adduct is the dominant epitope after MDA modification of proteins in atherosclerosis. Free radical biology & medicine 49: 1480-1486.
6. Fu S, Davies MJ, Stocker R, Dean RT (1998) Evidence for roles of radicals in protein oxidation in advanced human atherosclerotic plaque. The Biochemical journal 333 (Pt 3): 519-525.
7. Heinecke JW (1998) Oxidants and antioxidants in the pathogenesis of atherosclerosis: implications for the oxidized low density lipoprotein hypothesis. Atherosclerosis 141: 1-15.
8. Hill GE, Miller JA, Baxter BT, Klassen LW, Duryee MJ, et al. (1998) Association of malondialdehyde-acetaldehyde (MAA) adducted proteins with atherosclerotic-induced vascular inflammatory injury. Atherosclerosis 141: 107-116.
9. Uchida K (2006) Lipofuscin-like fluorophores originated from malondialdehyde. Free radical research 40: 1335-1338.
10. Holvoet P (1998) Oxidative modification of low-density lipoproteins in atherothrombosis. Acta cardiologica 53: 253-260.
11. Palinski W, Horkko S, Miller E, Steinbrecher UP, Powell HC, et al. (1996) Cloning of monoclonal autoantibodies to epitopes of oxidized lipoproteins from apolipoprotein E-deficient mice. Demonstration of epitopes of oxidized low density lipoprotein in human plasma. The Journal of clinical investigation 98: 800-814.
12. Palinski W, Rosenfeld ME, Yla-Herttuala S, Gurtner GC, Socher SS, et al. (1989) Low density lipoprotein undergoes oxidative modification in vivo. Proceedings of the National Academy of Sciences of the United States of America 86: 1372-1376.
13. Yla-Herttuala S, Palinski W, Rosenfeld ME, Parthasarathy S, Carew TE, et al. (1989) Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. The Journal of clinical investigation 84: 1086-1095.
14. Herrmann J, Soares SM, Lerman LO, Lerman A (2008) Potential role of the ubiquitin-proteasome system in atherosclerosis: aspects of a protein quality disease. Journal of the American College of Cardiology 51: 2003-2010.
15. Ketelhuth DF, Hansson GK (2011) Cellular immunity, low-density lipoprotein and atherosclerosis: break of tolerance in the artery wall. Thromb Haemost 106: 779-786.
16. Liu ZD, Wang L, Lu FH, Pan H, Zhao YX, et al. (2012) Increased Th17 cell frequency concomitant with decreased Foxp3+ Treg cell frequency in the peripheral circulation of patients with carotid artery plaques. Inflamm Res 61: 1155-1165.
17. Butcher MJ, Gjurich BN, Phillips T, Galkina EV (2012) The IL-17A/IL-17RA axis plays a proatherogenic role via the regulation of aortic myeloid cell recruitment. Circ Res 110: 675-687.
18. Danzaki K, Matsui Y, Ikesue M, Ohta D, Ito K, et al. (2012) Interleukin-17A deficiency accelerates unstable atherosclerotic plaque formation in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 32: 273-280.
19. Gao Q, Jiang Y, Ma T, Zhu F, Gao F, et al. (2010) A critical function of Th17 proinflammatory cells in the development of atherosclerotic plaque in mice. J Immunol 185: 5820-5827.
20. Lopes-Virella MF, Virella G (2010) Clinical significance of the humoral immune response to modified LDL. Clinical immunology 134: 55-65.
21. Ravandi A, Boekholdt SM, Mallat Z, Talmud PJ, Kastelein JJ, et al. (2011) Relationship of IgG and IgM autoantibodies and immune complexes to oxidized LDL with markers of oxidation and inflammation and cardiovascular events: results from the EPIC-Norfolk Study. Journal of lipid research 52: 1829-1836.
22. Tsimikas S, Brilakis ES, Lennon RJ, Miller ER, Witztum JL, et al. (2007) Relationship of IgG and IgM autoantibodies to oxidized low density lipoprotein with coronary artery disease and cardiovascular events. Journal of lipid research 48: 425-433.
23. Tsimikas S, Bergmark C, Beyer RW, Patel R, Pattison J, et al. (2003) Temporal increases in plasma markers of oxidized low-density lipoprotein strongly reflect the presence of acute coronary syndromes. J Am Coll Cardiol 41: 360-370.
24. Tsimikas S, Witztum JL, Miller ER, Sasiela WJ, Szarek M, et al. (2004) Highdose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in the MIRACL trial. Circulation 110: 1406-1412.
25. Tuma DJ, Thiele GM, Xu D, Klassen LW, Sorrell MF (1996) Acetaldehyde and malondialdehyde react together to generate distinct protein adducts in the liver during long-term ethanol administration. Hepatology 23: 872-880.
26. Thiele GM, Tuma DJ, Willis MS, Miller JA, McDonald TL, et al. (1998) Soluble proteins modified with acetaldehyde and malondialdehyde are immunogenic in the absence of adjuvant. Alcoholism, clinical and experimental research 22: 1731-1739.
27. Willis MS, Klassen LW, Tuma DJ, Sorrell MF, Thiele GM (2002) Adduction of soluble proteins with malondialdehyde-acetaldehyde (MAA) induces antibody production and enhances T-cell proliferation. Alcohol Clin Exp Res 26: 94-106.
28. Tuma DJ, Newman MR, Donohue TM Jr, Sorrell MF (1987) Covalent binding of acetaldehyde to proteins: participation of lysine residues. Alcohol Clin Exp Res 11: 579-584.
29. Willis MS, Klassen LW, Carlson DL, Brouse CF, Thiele GM (2004) Malondialdehyde-acetaldehyde haptenated protein binds macrophage scavenger receptor(s) and induces lysosomal damage. International immunopharmacology 4: 885-899.
30. Vehkala L, Ukkola O, Kesaniemi YA, Kahonen M, Nieminen MS, et al. (2013) Plasma IgA antibody levels to malondialdehyde acetaldehyde-adducts are associated with inflammatory mediators, obesity and type 2 diabetes. Ann Med 45: 501-510.
31. Sampi M, Veneskoski M, Ukkola O, Kesaniemi YA, Horkko S (2010) High plasma immunoglobulin (Ig) A and low IgG antibody titers to oxidized lowdensity lipoprotein are associated with markers of glucose metabolism. J Clin Endocrinol Metab 95: 2467-2475.
32. Lopes-Virella MF, Hunt KJ, Baker NL, Virella G, Moritz T, et al. (2012) The levels of MDA-LDL in circulating immune complexes predict myocardial infarction in the VADT study. Atherosclerosis 224: 526-531.
33. Furie KL, Goldstein LB, Albers GW, Khatri P, Neyens R, et al. (2012) Oral antithrombotic agents for the prevention of stroke in nonvalvular atrial fibrillation: a science advisory for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 43: 3442-3453.
34. Xu D, Thiele GM, Kearley ML, Haugen MD, Klassen LW, et al. (1997) Epitope characterization of malondialdehyde-acetaldehyde adducts using an enzymelinked immunosorbent assay. Chemical research in toxicology 10: 978-986.
35. Willerson JT, Ridker PM (2004) Inflammation as a cardiovascular risk factor. Circulation 109: II2-10.
36. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR (2002) Comparison of Creactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 347: 1557-1565.
37. Rolla R, Vay D, Mottaran E, Parodi M, Traverso N, et al. (2000) Detection of circulating antibodies against malondialdehyde-acetaldehyde adducts in patients with alcohol-induced liver disease. Hepatology 31: 878-884.
38. Palinski W, Yla-Herttuala S, Rosenfeld ME, Butler SW, Socher SA, et al. (1990) Antisera and monoclonal antibodies specific for epitopes generated during oxidative modification of low density lipoprotein. Arteriosclerosis 10: 325-335.
39. Horkko S, Binder CJ, Shaw PX, Chang MK, Silverman G, et al. (2000) Immunological responses to oxidized LDL. Free radical biology & medicine 28: 1771-1779.
40. Tsimikas S, Willeit P, Willeit J, Santer P, Mayr M, et al. (2012) Oxidationspecific biomarkers, prospective 15-year cardiovascular and stroke outcomes, and net reclassification of cardiovascular events. J Am Coll Cardiol 60: 2218-2229.
41. Mikuls TR, Holers VM, Parrish L, Kuhn KA, Conn DL, et al. (2006) Anti-cyclic citrullinated peptide antibody and rheumatoid factor isotypes in African Americans with early rheumatoid arthritis. Arthritis Rheum 54: 3057-3059.
42. Milioti N, Bermudez-Fajardo A, Penichet ML, Oviedo-Orta E (2008) Antigeninduced immunomodulation in the pathogenesis of atherosclerosis. Clin Dev Immunol 2008: 723539.
43. Aikawa M, Libby P (2004) The vulnerable atherosclerotic plaque: pathogenesis and therapeutic approach. Cardiovasc Pathol 13: 125-138.
44. Willis MS, Klassen LW, Tuma DJ, Sorrell MF, Thiele GM (2002) In vitro exposure to malondialdehyde-acetaldehyde adducted protein inhibits cell proliferation and viability. Alcohol Clin Exp Res 26: 158-164.
45. Willis MS, Thiele GM, Tuma DJ, Klassen LW (2003) T cell proliferative responses to malondialdehyde-acetaldehyde haptenated protein are scavenger receptor mediated. Int Immunopharmacol 3: 1381-1399.
46. Choudhary C, Kumar C, Gnad F, Nielsen ML, Rehman M, et al. (2009) Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 325: 834-840.
47. Sokolove J, Brennan MJ, Sharpe O, Lahey LJ, Kao AH, et al. (2013) Brief report: citrullination within the atherosclerotic plaque: a potential target for the anti-citrullinated protein antibody response in rheumatoid arthritis. Arthritis Rheum 65: 1719-1724.
48. Kummu O, Turunen SP, Prus P, Lehtimaki J, Veneskoski M, et al. (2014) Human monoclonal Fab and human plasma antibodies to carbamyl-epitopes cross-react with malondialdehyde-adducts. Immunology 141: 416-430.
49. Newby AC (2008) Metalloproteinase expression in monocytes and macrophages and its relationship to atherosclerotic plaque instability. Arterioscler Thromb Vasc Biol 28: 2108-2114.
50. Veneskoski M, Turunen SP, Kummu O, Nissinen A, Rannikko S, et al. (2011) Specific recognition of malondialdehyde and malondialdehyde acetaldehyde adducts on oxidized LDL and apoptotic cells by complement anaphylatoxin C3a. Free Radic Biol Med 51: 834-843.
51. Segev A, Strauss BH, Witztum JL, Lau HK, Tsimikas S (2005) Relationship of a comprehensive panel of plasma oxidized low-density lipoprotein markers to angiographic restenosis in patients undergoing percutaneous coronary intervention for stable angina. Am Heart J 150: 1007-1014.